Movement Disorders: Diffusion imaging parameters can detect and predict Parkinson's progress

Rasagiline has received attention as a potential disease improvement therapy for the treatment of Parkinson's disease (PD)
.

Whether rasagiline can change the disease is still questionable

David E.
Vaillancourt et al.
To determine whether rasagiline has a disease-improving effect in patients with Parkinson's disease for more than 1 year
.

Secondly, two diffusion magnetic resonance imaging pulse sequences were evaluated to determine the best sequence for assessing disease progression

David E.

This prospective, randomized, double-blind, placebo-controlled trial evaluated the efficacy of rasagiline at 1 mg/day for early PD within 12 months
.

Two kinds of diffusion magnetic resonance imaging pulse sequences were used to measure the 1-year change in the accumulation of free water in the substantia nigra (pSN), one with a repetition time (TR) of 2500 ms (short TR; n=90) and the other with a TR of 6400 ms (Long TR; n=75)

There was no significant difference in the absolute change of pSN free water accumulation among the groups (short TR: P=0.
346; long TR: P=0.
228)
.

No significant differences in secondary clinical results were found between the two groups

Long TR, not short TR, data showed that pSN free water increased significantly within one year (P=0.
025)
.

The third part of the dyskinesia society unified parkinson's disease motor function rating scale increased significantly within 1 year (P=0.

The study did not find evidence that rasagiline at 1 mg/day for more than 1 year has an ameliorating effect on Parkinson's disease
.

The pSN free water increased within 1 year, and the baseline free water was correlated with the progress of clinical exercise, proving the importance of diffusion imaging parameters for detecting and predicting the progress of PD, as well as the importance of using the long TR scan to evaluate the increase of free water in the progress of PD SN

The pSN free water increased within 1 year, and the baseline free water was correlated with the progress of clinical exercise, proving the importance of diffusion imaging parameters for detecting and predicting the progress of PD, and the importance of using the long TR scan to evaluate the increase of free water in the progress of PD SN

Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline [published online ahead of print, 2021 Nov 1].

Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline [published online ahead of print, 2021 Nov 1].
Mov Disord.
2021;10.
1002/mds.
28838.
doi:10.
1002/mds.
28838 Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline [published online ahead of print, 2021 Nov 1] Mov Disord 2021; 10.
1002 / mds.
28838 doi:.
.
.
10.
1002 / mds.
28838 in this message